載入中
NASDAQHealthcareBiotechnology
最新資料
US$8.275
−US$0.085 · -1.02%
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
一般交易時段
US$8.275
−US$0.085 · -1.02%
盤中時間採用ET。市場資料可能有所延遲。
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
日內區間
目前US$8.275
52週區間
目前US$8.275
盤中時間採用ET。市場資料可能有所延遲。
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
日內區間
目前US$8.275
52週區間
目前US$8.275
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 8.75億 USD | 4.51億 USD | 3.31億 USD | 2.71億 USD | 1.57億 USD |
| 銷貨成本 | 1907.5萬 USD | 1248.5萬 USD | 466.1萬 USD | 659.4萬 USD | 726.4萬 USD |
| 毛利 | 8.56億 USD | 4.38億 USD | 3.27億 USD | 2.64億 USD | 1.5億 USD |
| 研究與開發 | 1.66億 USD | 1.75億 USD | 2.17億 USD | 2.53億 USD | 2.09億 USD |
| 銷售、一般及管理費用 | 3.49億 USD | 2.66億 USD | 2.14億 USD | 1.59億 USD | 1.19億 USD |
| 營業費用 | 5.15億 USD | 4.41億 USD | 4.3億 USD | 4.13億 USD | 3.28億 USD |
| 利息收入 | 1066.8萬 USD | 1474.6萬 USD | 1577.7萬 USD | 512.7萬 USD | 6.2萬 USD |
| 利息支出 | 7887.2萬 USD | 9851.6萬 USD | 1.08億 USD | 9909.2萬 USD | 5929.4萬 USD |
| 折舊和攤銷 | 138.9萬 USD | 124.6萬 USD | 165.5萬 USD | 143.7萬 USD | 77.7萬 USD |
| 營業利益 | 3.41億 USD | −254.3萬 USD | −1.04億 USD | −1.48億 USD | −1.78億 USD |
| 淨利 | 2.64億 USD | −8888.1萬 USD | −2.27億 USD | −2.47億 USD | −1.84億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$19.00
上漲空間 129.61%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI7848.64萬0.00%2.3兆 USD0.03%US$380.45-0.29%
State Street SPDR S&P Biotech ETFXBI5800.78萬0.59%103.03億 USD0.35%US$148.27-2.07%
iShares Russell 2000 ETFIWM4794.47萬0.06%787.4億 USD0.19%US$275.81-0.75%
Vanguard Morningstar Small-Cap ETFVB2833.77萬0.02%1853億 USD0.03%US$286.57-0.55%
Vanguard Extended Market ETFVXF2782.35萬0.03%954億 USD0.05%US$231.54-0.85%
iShares Russell 2000 Growth ETFIWO1732.56萬0.13%139.17億 USD0.24%US$350.03-1.04%
Vanguard Morningstar Small-Cap Growth ETFVBK1624.15萬0.04%447億 USD0.05%US$336.71-1.22%
iShares Biotechnology ETFIBB1429.11萬0.13%108.2億 USD0.44%US$201.38-1.41%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Morningstar Small-Cap Growth ETFVBKiShares Biotechnology ETFIBBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
